Article source: “Shenzhen Business Daily”
May 11, 2021 A08 version
An adult is composed of approximately 40 trillion-60 trillion cells, which are divided into more than 200 different types. With the continuous deepening of human research on cells, cell therapy technology based on stem cells and immune cells has developed rapidly and has become a hot research and development hot spot in the field of life sciences today. Cell technology is expected to become one of the effective means to extend human lifespan and improve human health.
Shenzhen Beike Biotechnology Co., Ltd. (hereinafter referred to as Beike Biotechnology), established 16 years ago, is a company dedicated to basic cell research and clinical transformation, and is a representative of Shenzhen’s life and health industry. The “Research on Key Technology Innovation and Clinical Application of Allogeneic Mesenchymal Stem Cells in the Treatment of Refractory Lupus Erythematosus” that he participated in won the second prize of the National Technology Invention Award. This technology has an effective rate of 60%, reduces the 5-year mortality rate of refractory lupus erythematosus from 45% to 16%, and opens up a new treatment approach for refractory autoimmune diseases.
In addition to autoimmune diseases, cell therapy has shown great potential in many fields such as malignant tumors, regenerative medicine, and biopharmaceuticals. In recent years, many countries have regarded cell therapy as the focus and main direction of the development of the biomedical industry. More than 40 cell therapy products have been approved for marketing internationally. There are 111 stem cell clinical research institutions registered with the National Health Commission in China, with 100 registered projects, covering a variety of refractory diseases such as type 2 diabetes, myocardial infarction, pediatric cerebral palsy, Parkinson’s disease, etc. As a leader in the field of cells, Beike Biotech has cooperated with 5 hospitals to apply for and pass the registration of stem cell clinical research institutions, and has supported 5 stem cell clinical research projects to pass the registration, including the “randomized, parallel, controlled safety and effectiveness clinical study of human umbilical cord mesenchymal stem cells in the treatment of type 2 diabetes under different transplantation routes” at Peking University Shenzhen Hospital. It is reported that the project has started clinical research recruitment in 2020.
Stem cells also have high hopes during the fight against the new coronavirus epidemic. Zhang Xinmin, director of the Biological Center of the Ministry of Science and Technology, said at the press conference of the Joint Prevention and Control Mechanism of the State Council: “Stem cells are safe and effective in treating patients with new coronavirus pneumonia, and can quickly relieve or stop worsening of dyspnea in severe and critically ill patients. Improvements have been achieved in clinical manifestations, respiratory function, imaging examinations, etc., and cure levels can generally be achieved in 8-10 days. In addition, stem cells can block the process of pulmonary fibrosis and promote the repair of lung damage, showing their effect on lung damage. It has unique advantages in preventing pulmonary fibrosis and improving the long-term prognosis of patients. “Beike Biotech is also working on the front line of anti-epidemic work, quickly responded to the national call, and urgently devoted scientific research efforts to treat severe patients infected with new coronavirus pneumonia. It cooperated with Shenzhen Third People’s Hospital to apply for the “Clinical Research on Human Umbilical Cord Mesenchymal Stem Cells to Treat Severe Pneumonia Caused by Coronavirus” project, which was approved by the Guangdong Provincial Department of Science and Technology for the 2020 Guangdong Provincial Emergency Technology Research Project for the Prevention and Control of New Coronavirus. At the same time, the “Drug Research and Development of Mesenchymal Stem Cells for the Treatment of New Coronavirus Pneumonia” led by Beike Biotech was successfully selected into the Ministry of Science and Technology’s “Science and Technology Assists the Economy 2020” key project to contribute to the fight against the epidemic.
The Shenzhen Comprehensive Cell Bank operated by Beike Biotechnology was established by the Shenzhen Municipal Development and Reform Commission in accordance with the “Shenzhen Life and Health Industry Development Plan (2013-2020)” document and approved “Shenzhen Beike Biotechnology Co., Ltd. to build a Shenzhen Comprehensive Cell Bank” (Shenzhen Fa Gai [2014] No. 1717) to handle related cell resources and applications. With the new industrial development model of “Shenzhen Comprehensive Cell Bank + Regional Cell Preparation Center + Cell Quality Testing Platform”, it provides every family with internationally synchronized cell preparation and cell resource preservation services. Cell storage services currently provided include neonatal stem cell storage and adult peripheral blood immune cell storage. As the infrastructure of Shenzhen’s health industry, the Shenzhen Comprehensive Cell Science Museum regularly holds public welfare science popularization activities for the general public. You can make an appointment to visit the Shenzhen Comprehensive Cell Bank WeChat official account.